Related Experiment Videos
Adverse consequences of fluoxetine-MAOI combination therapy
J P Feighner1, W F Boyer, D L Tyler
1Feighner Research Institute, La Mesa, Calif.
The Journal of Clinical Psychiatry
|June 1, 1990
Summary
Combining fluoxetine with monoamine oxidase inhibitors (MAOIs) led to severe adverse effects, including the "serotonergic syndrome." Due to high risks and limited efficacy, this drug combination should generally be avoided in patients with refractory depression.
Area of Science:
- Psychiatry
- Clinical Pharmacology
Background:
- Refractory depression poses significant treatment challenges.
- Understanding drug interactions is critical for patient safety.
Purpose of the Study:
- To evaluate the safety and efficacy of combining fluoxetine with monoamine oxidase inhibitors (MAOIs).
- To investigate the adverse effects of concurrent or sequential fluoxetine-MAOI treatment in patients with refractory depression.
Main Methods:
- Open-label study of two patient series: 12 treated simultaneously with fluoxetine and MAOI, and 6 treated sequentially.
- Patients had treatment-resistant depression and often received other psychotropic medications.
Main Results:
- High incidence of adverse effects, notably the serotonergic syndrome (mental status changes, hypomania, confusion, myoclonus, hypertension, tremor, diarrhea).
- Lack of definite efficacy observed for the combination therapy.
- Potential for drug interaction due to long half-lives of fluoxetine and MAOIs.
Conclusions:
- Concurrent use of fluoxetine and MAOIs is generally not recommended due to significant risks.
- Sequential use also carries interaction risks due to drug half-lives.
- Caution is advised when switching between fluoxetine and MAOIs.